Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400714 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL22552830 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL29401757 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL119444 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL6290889 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL25168212 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL31220290 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL119688 | 0.93 | MDM4 (0.59) | MDM4TP53KMT2ATLR2CASP3 | |
| SCHEMBL5967446 | 0.93 | MDM4 (0.59) | MDM4TP53KMT2ATLR2CASP3 | |
| SCHEMBL31276348 | 0.93 | MDM4 (0.59) | MDM4TP53KMT2ATLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577259-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-11 | — | — | US | disclosed |
| US-7994168-B2 | Hexahydro-pyrazino[1,2-A]pyrimidine-4,7-dione derivatives substituted with amino acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-08-09 | — | — | US | disclosed |
| US-20070197539-A1 | HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1135374-B9 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1135374-B1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1135374-A1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6204282-B1 | TREATING CANCER, RETINOPATHY, ATHEROSCLEROSIS, VASCULAR RESTENOSIS, OR OSTEOPOROSIS. | SCHERING CORPORATION | 2001-03-20 | — | — | US | disclosed |
| WO-2000032578-A1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197539-A1 | HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS | TYMP, DPYD, P2RX7 | MDM4 277/4885TP53 539/4885IDO1 383/4885 |
| US-12577259-B2 | PCSK9 antagonist compounds | PCSK9, LDLR, PCSK6 | MDM4 4790/4885TP53 4774/4885IDO1 2614/4885 |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MDM4 4772/4885TP53 3596/4885IDO1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.